Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, China.
Curr Mol Med. 2019;19(3):157-163. doi: 10.2174/1566524019666190226104909.
The malignancy of small cell lung cancer (SCLC) is the highest amongst all lung cancer types. It is characterized by rapid growth, early occurrence of distant sites metastasis, poor survival rates and is initially sensitive to chemotherapy and radiotherapy. However, most patients eventually relapse or disease progresses because of chemotherapy resistance. Because of lack of effective second-line therapies, the prognosis of SCLC patients is usually poor. For the development of novel therapies, it is necessary to understand the mechanisms of chemotherapy resistance in SCLC. The mechanism is complex, because multiple factors could lead to chemotherapy resistance. An overview of multiple events triggering the formation of chemotherapy resistance phenotypes of SCLC cells is discussed.
小细胞肺癌(SCLC)的恶性程度在所有肺癌类型中最高。其特征为生长迅速、远处转移发生早、生存率差,并且对化疗和放疗初始敏感。然而,大多数患者最终因化疗耐药而复发或疾病进展。由于缺乏有效的二线治疗方法,SCLC 患者的预后通常较差。为了开发新的治疗方法,有必要了解 SCLC 化疗耐药的机制。该机制很复杂,因为多种因素可导致化疗耐药。本文概述了触发 SCLC 细胞产生化疗耐药表型的多种事件。